Mylan Inc (MYL) News $MYL
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
Mixed News for Pfizer: A Good Chance to Buy?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:30AM CDT
Last week was unusually eventful for Pfizer . The company, along with partner Bristol-Myers Squibb won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from a pneumonia vaccine study that...
After Yesterday's Rally of 1.69% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:05PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Mylan Rises 1.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:04PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
15.8% Return Seen to Date on SmarTrend Mylan Call (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 11:17AM CDT
SmarTrend identified an Uptrend for Mylan (NASDAQ:MYL) on February 14th, 2014 at $46.13. In approximately 1 month, Mylan has returned 15.85% as of today's recent price of $53.44.
Mylan Earnings Hindsight: Down 6.5% in Last 18 Days (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 6:58AM CDT
Two weeks ago on February 27th, 2014 Mylan (NASDAQ:MYL) reported earnings and analysts, on average, expected earnings of $0.75 on sales of $1.8 billion. The company actually reported EPS of $0.78 on sales of $1.8 billion, beating EPS estimates by $0.03 and beating revenue estimates by $3.1 million. Shares of Mylan have slipped from $56.27 to $52.63, representing a loss of 6.5%, since the company reported earnings 18 days ago.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Mar 17, 6:57AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:20PM CDT
Both Actavis and Mylan are looking to launch their generic versions of Celebrex in May provided they gain final FDA approval.
Horizon Pharma Banks On Two-For-One Arthritis Drugs
at Investor's Business Daily - Fri Mar 14, 1:05PM CDT
Specialty drug company Horizon Pharma (HZNP) is on a roll with two arthritis drugs, Duexis and Vimovo. Both treat arthritis pain and protect against ulcers, a two-for-one bang that most other drugs treating arthritis don't provide. Like most...
Mylan (MYL) Is Today's Unusual Social Activity Stock
at The Street - Fri Mar 14, 9:16AM CDT
Trade-Ideas LLC identified Mylan (MYL) as an unusual social activity candidate
Unfavorable Ruling for Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 12:50PM CDT
The court found Pfizer's reissue patent for Celebrex to be invalid.
Mylan (MYL) Breaks Through Support at $52.39
Comtex SmarTrend(R) - Thu Mar 13, 12:30PM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $53.14 and have already reached the first level of support at $52.39. Should the shares continue to fall, the support pivots of $51.72 and $50.30 will be of interest.
Mylan Comments on Favorable Ruling in Generic Celebrex® Patent Suit
PR Newswire - Thu Mar 13, 5:30AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Mylan opens Critical Care Segment in India
M2 - Wed Mar 12, 8:19AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the launch of a Critical Care segment in India, by its subsidiary Mylan Pharmaceuticals Private Limited.
Mylan proposes JoEllen Lyons Dillon for election to board of directors
M2 - Wed Mar 12, 8:04AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the nomination of JoEllen Lyons Dillon as a candidate for election to Mylan's Board.
Mylan introduces Naloxone Hydrochloride Injection
M2 - Wed Mar 12, 7:59AM CDT
Pharmaceutical company Mylan Inc ((NASDAQ GS:MYL) announced on Tuesday the launch of Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
Mylan Launches Naloxone Hydrochloride Injection
PR Newswire - Tue Mar 11, 2:03PM CDT
Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Mylan's Naloxone Hydrochloride Injection is preservative free and not made with natural rubber latex.
Mylan Introduces Critical Care Segment in India
PR Newswire - Tue Mar 11, 2:00PM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome®, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with $2.6 billion* in annual sales.1
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
Mixed News for Pfizer: A Good Chance to Buy?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:30AM CDT
Last week was unusually eventful for Pfizer . The company, along with partner Bristol-Myers Squibb won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from a pneumonia vaccine study that...
After Yesterday's Rally of 1.69% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:05PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Mylan Rises 1.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Mar 17, 4:04PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $52.86 to a high of $54.22. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $53.89 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
15.8% Return Seen to Date on SmarTrend Mylan Call (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 11:17AM CDT
SmarTrend identified an Uptrend for Mylan (NASDAQ:MYL) on February 14th, 2014 at $46.13. In approximately 1 month, Mylan has returned 15.85% as of today's recent price of $53.44.
Mylan Earnings Hindsight: Down 6.5% in Last 18 Days (MYL)
Comtex SmarTrend(R) - Mon Mar 17, 6:58AM CDT
Two weeks ago on February 27th, 2014 Mylan (NASDAQ:MYL) reported earnings and analysts, on average, expected earnings of $0.75 on sales of $1.8 billion. The company actually reported EPS of $0.78 on sales of $1.8 billion, beating EPS estimates by $0.03 and beating revenue estimates by $3.1 million. Shares of Mylan have slipped from $56.27 to $52.63, representing a loss of 6.5%, since the company reported earnings 18 days ago.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Mar 17, 6:57AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:20PM CDT
Both Actavis and Mylan are looking to launch their generic versions of Celebrex in May provided they gain final FDA approval.
Horizon Pharma Banks On Two-For-One Arthritis Drugs
at Investor's Business Daily - Fri Mar 14, 1:05PM CDT
Specialty drug company Horizon Pharma (HZNP) is on a roll with two arthritis drugs, Duexis and Vimovo. Both treat arthritis pain and protect against ulcers, a two-for-one bang that most other drugs treating arthritis don't provide. Like most...
Mylan (MYL) Is Today's Unusual Social Activity Stock
at The Street - Fri Mar 14, 9:16AM CDT
Trade-Ideas LLC identified Mylan (MYL) as an unusual social activity candidate
Unfavorable Ruling for Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 12:50PM CDT
The court found Pfizer's reissue patent for Celebrex to be invalid.
Mylan (MYL) Breaks Through Support at $52.39
Comtex SmarTrend(R) - Thu Mar 13, 12:30PM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $53.14 and have already reached the first level of support at $52.39. Should the shares continue to fall, the support pivots of $51.72 and $50.30 will be of interest.
Mylan Comments on Favorable Ruling in Generic Celebrex® Patent Suit
PR Newswire - Thu Mar 13, 5:30AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Mylan opens Critical Care Segment in India
M2 - Wed Mar 12, 8:19AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the launch of a Critical Care segment in India, by its subsidiary Mylan Pharmaceuticals Private Limited.
Mylan proposes JoEllen Lyons Dillon for election to board of directors
M2 - Wed Mar 12, 8:04AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the nomination of JoEllen Lyons Dillon as a candidate for election to Mylan's Board.
Mylan introduces Naloxone Hydrochloride Injection
M2 - Wed Mar 12, 7:59AM CDT
Pharmaceutical company Mylan Inc ((NASDAQ GS:MYL) announced on Tuesday the launch of Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
Mylan Launches Naloxone Hydrochloride Injection
PR Newswire - Tue Mar 11, 2:03PM CDT
Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Mylan's Naloxone Hydrochloride Injection is preservative free and not made with natural rubber latex.
Mylan Introduces Critical Care Segment in India
PR Newswire - Tue Mar 11, 2:00PM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome®, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with $2.6 billion* in annual sales.1
